Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis

Fig. 2

Evaluation of variables associated with interstitial lung disease (ILD) in three patents with systemic sclerosis before mesenchymal stem cell transplantation (MSCT), and at 6 months and 12 months after MSCT. a Diffusing capacity of the lung for carbon monoxide (DLco). b Forced vital capacity (FVC). *P < 0.05. Pts patients

Back to article page